首页> 外文期刊>International journal of oncology >Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: Crosstalk among proteasome, autophagy-lysosome and ER stress
【24h】

Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: Crosstalk among proteasome, autophagy-lysosome and ER stress

机译:硼替佐米联合巴氟霉素A1联合治疗可增强U266骨髓瘤细胞的杀细胞作用并诱导内质网应激:蛋白酶体,自噬-溶酶体和内质网应激之间的串扰

获取原文
       

摘要

Bortezomib (BZ), a first line 26S proteasome inhibitor, induces a potent cytocidal effect with caspase-3 activation in multiple myeloma (MM) cell lines. Since IκBα is a substrate of the proteasome, the initial rationale for using BZ in MM has been to inhibit NF-κB. However, BZ rather activated NF-κB activity in U266 cells. BZ induces autophagy as well as endoplasmic reticulum (ER) stress in various cell lines tested. Inhibition of initial autophagosome formation by treatment with either 3-methyladenine or siRNA for LC3B in U266 cells and knockdown of the atg5 gene in a murine embryonic fibroblastic cell line all resulted in attenuation of BZ-induced cell death. In contrast, combined treatment with BZ and bafilomycin A1 (BAF), which is a specific inhibitor of vacuolar-ATPase and is used as an autophagy inhibitor at the late stage, resulted in synergistic cytotoxicity, compared with that by either BZ or BAF alone. BAF treatment also induced ER stress, but the kinetics of inductions of ER stress-related genes [e.g. CHOP (GADD153) and GRP78] completely differed between BZ- and BAF-treatments: BZ induced these ER stress markers within 8 h, whereas treatment with BAF required more than 48 h in U266 cells. In order to synchronize ER stress, we pre-treated U266 cells with BAF for 48 h, followed with BZ for 48 h. The sequential treatment with BAF and BZ induced a further enhanced cytotoxicity, compared with the simultaneous combination of BAF and BZ. These data suggest crosstalk among the ubiquitin-proteasome system, the autophagy-lysosome system, and ER stress. Controlling these interactions and kinetics appears to have important implications for optimizing clinical cancer treatment including MM-therapy.
机译:硼替佐米(BZ)是一系26S蛋白酶体抑制剂,可在多发性骨髓瘤(MM)细胞系中诱导具有caspase-3激活作用的有效杀细胞作用。由于IκBα是蛋白酶体的底物,因此在MM中使用BZ的最初理由是抑制NF-κB。然而,BZ激活了U266细胞中的NF-κB活性。 BZ在各种测试的细胞系中诱导自噬以及内质网(ER)应激。通过用3-甲基腺嘌呤或siRNA处理U266细胞中的LC3B来抑制初始自噬体的形成以及鼠胚胎成纤维细胞系中atg5基因的敲低均导致BZ诱导的细胞死亡减弱。相比之下,与BZ或BAF单独使用相比,与液泡-ATPase的特异性抑制剂BZ和bafilomycin A1(BAF)的组合治疗在后期被用作自噬抑制剂,导致协同的细胞毒性。 BAF处理也诱导内质网应激,但诱导内质网应激相关基因的动力学[例如: CHOP(GADD153)和GRP78]在BZ和BAF处理之间完全不同:BZ在8小时内诱导了这些ER应激标志物,而在U266​​细胞中用BAF处理需要48小时以上。为了同步ER应激,我们用BAF预处理U266细胞48小时,然后使用BZ预处理48 h。与同时使用BAF和BZ的组合相比,使用BAF和BZ的顺序治疗可进一步增强细胞毒性。这些数据表明泛素-蛋白酶体系统,自噬-溶酶体系统和内质网应激之间存在串扰。控制这些相互作用和动力学似乎对优化包括MM治疗在内的临床癌症治疗具有重要意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号